| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | 0% | $205,220,969 | +$3,481,297 | 11,063,125 | +1.7% | RA Capital Management, L.P. | 31 Mar 2025 |
| Capital World Investors | 8.7% | +15% | $279,357,901 | +$40,811,002 | 9,822,711 | +17% | Capital World Investors | 30 Sep 2025 |
| Forbion Capital Fund IV Cooperatief U.A. | 8.3% | -12% | $223,140,090 | -$30,222,313 | 9,316,914 | -12% | ForGrowth NAP B.V. | 26 Sep 2025 |
| Frazier Life Sciences X, L.P. | 7.7% | +17% | $245,264,825 | +$36,858,297 | 8,623,939 | +18% | Frazier Life Sciences Public Fund, L.P. | 01 Nov 2025 |
| FMR LLC | 5.7% | $224,967,479 | 6,412,984 | FMR LLC | 31 Dec 2025 | |||
| BCLS II Investco, LP | 4.7% | -53% | $214,462,841 | -$241,180,844 | 5,376,356 | -53% | BCLS Fund III Investments, LP | 02 Dec 2025 |
| VIKING GLOBAL INVESTORS LP | 3.7% | -40% | $144,476,598 | -$95,375,616 | 4,203,567 | -40% | VIKING GLOBAL INVESTORS LP | 31 Dec 2025 |
As of 31 Dec 2025, 182 institutional investors reported holding 118,571,782 shares of NewAmsterdam Pharma Co N.V. - Ordinary Shares, nominal value EUR0.12 per share (NAMS). This represents 104% of the company’s total 113,609,919 outstanding shares.
The largest institutional shareholders of NewAmsterdam Pharma Co N.V. - Ordinary Shares, nominal value EUR0.12 per share (NAMS) together control 89% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 15% | 16,943,774 | +1.4% | 16% | $594,387,592 |
| Capital World Investors | 8.8% | 9,984,000 | +1.6% | 0.05% | $350,238,720 |
| RA CAPITAL MANAGEMENT, L.P. | 8.4% | 9,550,191 | -5.8% | 3.4% | $335,020,700 |
| FCPM III SERVICES B.V. | 8.1% | 9,198,900 | -0.15% | 42% | $322,697,412 |
| Bain Capital Life Sciences Investors, LLC | 6.4% | 7,306,566 | -32% | 20% | $256,314,335 |
| FMR LLC | 5.6% | 6,412,984 | +16% | 0.01% | $224,967,480 |
| WELLINGTON MANAGEMENT GROUP LLP | 4.4% | 5,033,175 | +25% | 0.03% | $176,563,779 |
| VIKING GLOBAL INVESTORS LP | 3.7% | 4,203,567 | -35% | 0.39% | $147,461,130 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 3.7% | 4,164,789 | -2.4% | 1.9% | $146,100,798 |
| JENNISON ASSOCIATES LLC | 3.1% | 3,489,221 | -17% | 0.07% | $122,401,874 |
| Duquesne Family Office LLC | 2.7% | 3,070,146 | +60% | 2.6% | $107,701,000 |
| Medicxi Ventures Management (Jersey) Ltd | 2.5% | 2,869,565 | 0% | 12% | $100,664,340 |
| Polar Capital Holdings Plc | 2.4% | 2,776,222 | -4.7% | 0.45% | $97,389,868 |
| JANUS HENDERSON GROUP PLC | 2.1% | 2,341,723 | +11% | 0.04% | $82,299,855 |
| Capital International Investors | 1.8% | 2,062,535 | 0% | 0.01% | $72,353,728 |
| MAVERICK CAPITAL LTD | 1.7% | 1,894,226 | +26% | 0.71% | $66,449,448 |
| GOLDMAN SACHS GROUP INC | 1.5% | 1,725,662 | +96% | 0.01% | $60,536,223 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.2% | 1,406,631 | -45% | 0.07% | $49,344,615 |
| ALLIANCEBERNSTEIN L.P. | 1.1% | 1,300,875 | -39% | 0.01% | $45,634,695 |
| Castle Hook Partners LP | 0.96% | 1,085,008 | 0.55% | $38,062,080 | |
| Cormorant Asset Management, LP | 0.88% | 1,000,000 | -54% | 2% | $35,080,000 |
| JPMORGAN CHASE & CO | 0.88% | 999,976 | -23% | 0% | $35,079,158 |
| UBS Group AG | 0.79% | 899,442 | +17% | 0.01% | $31,552,425 |
| First Turn Management, LLC | 0.79% | 893,473 | +25% | 3.6% | $31,343,033 |
| BlackRock, Inc. | 0.75% | 849,779 | +37% | 0% | $29,810,247 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 118,571,782 | $4,159,988,277 | -$60,031,059 | $35.08 | 182 |
| 2025 Q3 | 120,390,588 | $3,423,902,136 | +$122,882,388 | $28.44 | 135 |
| 2025 Q2 | 116,368,291 | $2,107,516,504 | +$92,203,105 | $18.11 | 130 |
| 2025 Q1 | 111,177,846 | $2,278,669,708 | +$247,823,372 | $20.47 | 126 |
| 2024 Q4 | 98,611,632 | $2,534,320,573 | +$569,548,998 | $25.70 | 130 |
| 2024 Q3 | 77,090,356 | $1,279,730,929 | +$65,939,934 | $16.60 | 100 |
| 2024 Q2 | 72,010,250 | $1,383,367,935 | -$7,907,090 | $19.21 | 90 |
| 2024 Q1 | 72,152,341 | $1,706,357,479 | +$242,490,357 | $23.65 | 76 |
| 2023 Q4 | 61,897,680 | $691,396,295 | -$81,202 | $11.17 | 32 |
| 2023 Q3 | 50,178,896 | $464,099,871 | +$5,440,463 | $9.25 | 35 |
| 2023 Q2 | 48,833,993 | $580,635,231 | +$184,129,037 | $11.89 | 29 |
| 2023 Q1 | 33,346,896 | $444,858,187 | +$689,119 | $13.26 | 19 |
| 2022 Q4 | 33,516,836 | $362,234,361 | +$362,234,361 | $10.90 | 14 |